JPMorgan Chase & Co. 13D and 13G filings for Coherus BioSciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-07 2:45 pm Sale |
2023-11-30 | 13G | Coherus BioSciences, Inc. CHRS |
J P MORGAN CHASE & CO JPM |
124,796 0.100% |
-5,538,974 (-97.80%) |
Filing |
| 2023-01-18 1:30 pm Sale |
2022-12-30 | 13G | Coherus BioSciences, Inc. CHRS |
J P MORGAN CHASE & CO JPM |
5,663,770 7.200% |
-691,417 (-10.88%) |
Filing |
| 2022-01-07 3:41 pm Purchase |
2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
J P MORGAN CHASE & CO JPM |
6,355,187 8.200% |
1,392,505 (+28.06%) |
Filing |
| 2021-01-08 11:43 am Purchase |
2020-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
J P MORGAN CHASE & CO JPM |
4,962,682 6.800% |
1,494,928 (+43.11%) |
Filing |